Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNZ-1 in Moderate to Severe Alopecia Areata
NCT03532958Phase 2Withdrawn
- Sponsor
- Equillium, Inc.
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules, PEGylated Peptides
01
Overview
A Phase 2 trial of BNZ-1 in alopecia areata, sponsored by Equillium, Inc.. Planned start Oct 2021; status: withdrawn.
02
Drugs
BNZ-1
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03532958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532958.